Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
setrobuvir + peginterferon alfa-2a + ribavirin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Subcutaneous
01
Overview
**Setrobuvir + peginterferon alfa-2a + ribavirin** is a triple combination therapy evaluated for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotype 1, in treatment-naïve patients. - **Setrobuvir** is a small molecule inhibitor targeting the HCV NS5B non-nucleoside polymerase, blocking viral RNA replication. - **Peginterferon alfa-2a** is a recombinant pegylated form of interferon alpha, working as an immunomodulator that enhances the host's antiviral defense by binding to the interferon alpha receptor and promoting expression of genes involved in viral clearance. - **Ribavirin** is a nucleoside analogue with broad-spectrum antiviral activity, interfering with viral RNA synthesis and inducing lethal mutagenesis in the HCV genome. When used together, the combination aims to induce a sustained virologic response (SVR), measured by undetectable levels of HCV RNA 24 weeks after completing therapy. Clinical studies have tested this regimen with a lead-in phase of peginterferon alfa-2a and ribavirin, followed by the addition of setrobuvir, typically administered orally alongside subcutaneous peginterferon alfa-2a and oral ribavirin[3].
- Other names
- setrobuvir + peginterferon alfa-2a + ribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on setrobuvir + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on setrobuvir + peginterferon alfa-2a + ribavirin.